Journals / Erciyes Tıp Dergisi / 2006 / Cilt: 28 - Sayı: 3

The effect of atorvastatin on plasma homocysteine, vitamin B12 and folic acid levels

Atorvastatin kullanımının homositein, vitamin B12 ve folik asit seviyelerine etkisi

Pages
111–119
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

There was a negative but not significant correlation between plasma tHcy concentration, and serum folate and vitamin B12 for atorvastatin group and between plasma tHcy concentration and vitamin B12 for control group.Conclusion: No significant differences in plasma tHcy concentration between 2 groups could be attributed to usage of low dose of atorvastatin and inadequate intake of folate and vitamin B12 of patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of present study is to investigate the effect of atorvastatin (statin group drugs, 20mg/day) intake on plasma homocysteine (tHcy), vitamin B12 and folic acid concentrations.
📊
Key Findings & Data:Material and methods: The sample of this study consists of 20 voluntary patients, who applied to Cardiology Outpatient clinic of Başkent University Hospital, Ankara, from November 2003 to February 2004.
💡
Conclusion & Impact:There was a negative but not significant correlation between plasma tHcy concentration, and serum folate and vitamin B12 for atorvastatin group and between plasma tHcy concentration and vitamin B12 for control group.Conclusion: No significant differences in plasma tHcy concentration between 2 groups could be attributed to usage of low dose of atorvastatin and inadequate intake of folate and vitamin B12 of patients.
🔬Design:Research Article
📍Scope:2003 Verileri
⚙️Variables:Domain Parameters

Abstract

Purpose: The aim of present study is to investigate the effect of atorvastatin (statin group drugs, 20mg/day) intake on plasma homocysteine (tHcy), vitamin B12 and folic acid concentrations. Material and methods: The sample of this study consists of 20 voluntary patients, who applied to Cardiology Outpatient clinic of Başkent University Hospital, Ankara, from November 2003 to February 2004. Ten patients used atorvastatin 20 mg/day for a mean (±SD) duration of 24.14±6.5 months (range, 3.6 to 156 months) and the remaining 10 patients did not use any atorvastatin and were used as a control subjects in this study. Anthropometric measurements, a three-day 24-h dietary record and biochemical parameters such as plasma tHcy, folate and vitamin B12 level were measured. Results: Age, BMI, body fat, waist/hip ratio of each patient were similar (p>0.05). When the energy and nutrient intake of the groups were compared, no significant differences were found (p>0.05). Serum folate levels of atorvastatin group were higher than the control group but there were no significant differences in vitamin B12, plasma tHcy, total cholesterol and its fractions between two groups. Plasma triglyceride levels of the control group were higher than the atorvastatin group. There was a negative but not significant correlation between plasma tHcy concentration, and serum folate and vitamin B12 for atorvastatin group and between plasma tHcy concentration and vitamin B12 for control group.Conclusion: No significant differences in plasma tHcy concentration between 2 groups could be attributed to usage of low dose of atorvastatin and inadequate intake of folate and vitamin B12 of patients.

Özet

Amaç: Sunulan çalışmanın amacı plazma homosistein, vitamin B12 ve folik asit konsantrasyonu üzerine atorvastatin (statin grubu ilaçlar, 20mg/gün) alımının etkisini araştırmaktır.Gereç ve Yöntem: Çalışma Kasım 2003 ile Şubat 2004 tarihleri arasında Ankara Başkent Üniversitesi Hastanesi Kardiyoloji polikliniğine başvuran toplam 20 gönüllü hasta üzerinde yapılmıştır. Hastalardan 10’u atorvastatini (20 mg/gün) 24.1±46.5 ay (3.6-156 ay) süresince kullanırken, kontrol grubunu oluşturan 10 hasta daha önce hiçbir statin grubu ilaç kullanmamıştır. Bireylerin antropometrik ölçümleri, 24 saatlik besin tüketim kayıtları alınmış ve biyokimyasal parametrelerinde plazma homosistein, folat ve vitamin B12 düzeyleri çalışılmıştır. Bulgular: Her iki gruptaki hastaların yaş, BKI, vücut yağı, bel/kalça oranı benzerdir (p>0.05). Grupların enerji ve besin öğeleri alımları karşılaştırıldığında aralarında anlamlı bir fark saptanmamıştır (p>0.05). Atorvastatin grubunda serum folat (p0.05) bir ilişki bulunmuştur.Sonuç: Plazma tHyc konsantrasyonunun atorvastatin alan ve almayan guruplar arasında farklı bulunmamış olması çalışmada kullanılan atorvastatin dozunun düşük olması, çalışma gurubundaki bireylerin folat ve vitamin B12 alımlarının yetersiz olmasına bağlanabilir.

🔖

Cite This Article

KARABUDAK, E., AKSOY, H., KIZILTAN, G., TAYFUN, E. (2022). The effect of atorvastatin on plasma homocysteine, vitamin B12 and folic acid levels. Erciyes Tıp Dergisi, Cilt: 28 - Sayı: 3, 111–119. https://ajindex.com/articles/502758

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Kang SS, Wong PW, and Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Ann Rev Nutr 1992;12:279-298
  2. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Eng J Med 1997;337:230-236
  3. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-1057
  4. Clarke R, et al. HyperhomocysteinemiaÊ: An independent risk factor for vascular disease. N Engl J Med 1991;3324:1149-1154
  5. Krummel D. Nutrition in cardiovascular disease. In:Mahan KL, Arlin M. (eds), Krause’s Food Nutrition and Diet Therapy, WB Saunders Company, USA, 2000, pp 558-595
  6. Scandinavan Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-1389
  7. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Effect of atorvastatin on plasma fibrinogen. Lancet 1998;351:569-570
  8. Giral P, Bruckert E,Jocob M, Chopman JM, Foglietti M.,Turpin G. Homocysteine and lipid lowering agents-A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 2001;154:421-427
  9. Selhurb J, Jacques PF, Wilson PWP, Rush D, Rosenbergh IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693-2698
  10. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1990;263:1646-1651
  11. Allen RH, Stabler SP, Savage DG, Lindenbaum J. Metabolic abnormalities in cobalamin (vitamin B-12) and folate deficiency. Faseb J 1993;7:1344-1353
  12. Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem 1998;1:228-237
  13. Bronstrup A, Hages M, Prin z-Longenohl R, et al. Effects of folic acid and combination of folic acid and vitamin B12 on plasma homocysteine concentrations in healthy young Women. Am J Clin Nutr 1998;68:1104-1110
  14. National Research Council. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, D.C: National Academy Press, 2000
  15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparat